Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment"

J Hepatol. 2019 Jan;70(1):211-212. doi: 10.1016/j.jhep.2018.09.026. Epub 2018 Oct 19.

Author

George N Ioannou¹

Affiliation

¹ Division of Gastroenterology, Department of Medicine Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, United States; Research and Development, Veterans Affairs Puget Sound Healthcare System, Seattle, WA, United States. Electronic address: georgei@medicine.washington.edu.

PMID: 30348467
DOI: 10.1016/j.jhep.2018.09.026

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Antiviral Agents*
Carcinoma, Hepatocellular*
Hepatitis C*
Hepatitis C, Chronic*
Humans
Liver Neoplasms*

Substances

Antiviral Agents

Grants and funding

R01 CA196692/CA/NCI NIH HHS/United States